Anti-CD27 Polyclonal Antibody for WB, ELISA - P26842

Core Product Specifications and Parameters

Biological Background: CD27 Function and Localization

• CD27 antigen (aliases: T14, TNFRSF7, Tp55) is a member of the tumor necrosis factor receptor superfamily, functioning as a costimulatory immune-checkpoint receptor on the surface of T-cells, NK-cells, and B-cells.
• Its primary ligand is CD70 (CD27L), and the CD70-CD27 pathway drives antigen-specific T-cell activation and expansion, providing immune surveillance of B-cells. Related references: PMID:28011863
• Mechanistically, CD70 binding activates the TRAF2-PTPN6 axis, inhibiting LCK phosphorylation to promote T-cell memory adaptations. Related references: PMID:38354704
• Additionally, CD27 engagement on early progenitor cells delivers a negative feedback signal to leukocyte differentiation, modulating hematopoiesis, and it negatively regulates Th2 lymphocyte function in adipose tissue.
• The protein is a single-pass transmembrane receptor localized exclusively at the cell membrane and contains a signal peptide, extracellular TNFR-like cysteine-rich domains, a transmembrane helix, and a cytoplasmic tail.
• Key post‑translational modifications include N‑linked glycosylation and phosphorylation; the receptor is also characterized by disulfide bonds that stabilize its extracellular structure.
• CD27 is broadly expressed on most T‑lymphocytes, and its signaling is implicated in apoptosis, disease variants of lymphoproliferative syndromes, and hematopoietic regulation.

Experimental Guidance and Technical Tips

• The immunogen corresponds to the extracellular domain (amino acids 20–191) of human CD27, suggesting the antibody likely recognizes epitopes within the ligand-binding region; consider performing epitope mapping if precise binding site information is needed.
• For Western blot, the predicted molecular weight is 29 kDa; however, due to glycosylation, the observed band may migrate at a higher apparent molecular weight. Validate under reducing and non‑reducing conditions as appropriate.
• The antibody is reported to cross‑react with mouse CD27, making it a potential tool for comparative studies; always verify cross‑reactivity in the relevant experimental system.
• ELISA applications may benefit from pairing this polyclonal antibody with a monoclonal detection antibody in a sandwich format; optimize coating and detection conditions empirically.
• As a polyclonal preparation, lot‑to‑lot consistency should be monitored in quantitative assays; consider using a recombinant monoclonal antibody if stringent reproducibility is required.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio offers diagnostic manufacturers, contract research organizations, and academic laboratories a streamlined channel to procure validated IVD raw materials like this anti‑CD27 polyclonal antibody. Our portfolio spans a wide range of immune‑checkpoint and T‑cell targets, including optimized monoclonal/polyclonal antibodies, matched antibody pairs, and bulk ancillary reagents. Through expert consultation and global supply networks, we help accelerate your CD27‑based assay development and rare‑target sourcing needs.